Dr. Richard David

Dr. Richard David
Dr. Richard David serves as Chief Medical Officer for the Greater Los Angeles Division of Genesis Healthcare Partners, the largest Urology group in California. He also serves as medical director for the Cancer Center of Excellence. Additionally, he serves as Medical Director of Clinical Research for Genesis Healthcare. Dr. David received a Masters in Medical Management (MMM) degree from the Marshall School of Business at USC and serves as Clinical Professor of Urology (Vol) at the David Geffen School of Medicine at UCLA. His clinical and research interest includes minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received “Super Doctor” designation 14 times. Dr. David obtained his undergraduate education at Stanford University, Stanford, CA, and his medical degree at Thomas Jefferson University, Philadelphia, PA. He trained in general surgery and completed his urology residency at UCLA Medical Center, Los Angeles, CA. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the California Urologic Association, American Association of Clinical Urologists, American Association of Physician Leaders and the Sexual Medicine Society.

Languages Spoken:

English, Spanish

Medical School:

Jefferson Medical College

Residency:

UCLA

Undergraduate:

Stanford University

Locations

Genesis Healthcare Partners Sherman Oaks, CA

5522 Sepulveda BlvdSherman Oaks, California, 91411United States
818-990-5020 | Visit Website

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only